12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CR845: Phase II data

A double-blind, U.S. Phase II trial in 203 women undergoing a laparoscopic hysterectomy showed that a pre- and post-operative dose of 0.04 mg/kg IV CR845 met the primary endpoint of reducing total morphine consumption over the first 24 hours post-surgery vs. pre- and post-operative placebo. Specifically, pre- and post-operative CR845 reduced total morphine consumption by about 33% vs. placebo (p<0.05). On secondary endpoints, pre-...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >